Trial Investigating AzurRx’s Replacement Therapy for EPI Completes 75% Enrollment
AzurRx BioPharma announced that its clinical trial testing MS1819-SD as a replacement enzyme therapy for exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (inflammation of the pancreas) has enrolled three new patients, completing 75 percent of its goal. Although patients with cystic fibrosis (CF) are excluded from the trial,…